We have previously shown that combined
amylin +
leptin agonism elicits synergistic
weight loss in diet-induced obese (DIO) rats. Here, we assessed the comparative efficacy of
amylin,
leptin, or
amylin +
leptin in the maintenance of
amylin +
leptin-mediated
weight loss. DIO rats pretreated with the combination of rat
amylin (50 microg/kg/day) and murine
leptin (125 microg/kg/day) for 4 weeks were subsequently infused with either vehicle,
amylin,
leptin, or
amylin +
leptin for an additional 4 weeks. Food intake,
body weight, body composition, plasma parameters, and the expression of key metabolic genes in liver and white adipose tissue (WAT) were assessed.
Amylin +
leptin treatment (weeks 0-4) reduced
body weight to 87.5% of baseline. Rats subsequently maintained on vehicle or
leptin regained all weight (to 104.2 and 101.2% of baseline, respectively), those maintained on
amylin had partial weight regain (97.0%). By contrast,
weight loss was largely maintained with continued
amylin +
leptin treatment (91.4%), associated with
a 10% decrease in adiposity. Cumulative food intake (weeks 5-8) was reduced by
amylin and
amylin +
leptin, but not by
leptin alone.
Amylin +
leptin, but not
amylin or
leptin alone, reduced plasma
triglycerides (by 55%), total
cholesterol (by 19%), and
insulin (by 57%) compared to vehicle.
Amylin +
leptin also reduced hepatic
stearoyl-CoA desaturase-1 (Scd1)
mRNA, and increased WAT
mRNA levels of
adiponectin,
fatty acid synthase (Fasn), and
lipoprotein lipase (Lpl). We conclude that, in DIO rats, maintenance of
amylin +
leptin-mediated
weight loss requires continued treatment with both agonists, and is accompanied by sustained improvements in body composition, and indices of lipid metabolism and
insulin sensitivity.